Patent · US Active

Anti-CD30L antibodies and uses thereof

US11866505B2 · kind B2 · utility

0Cited by

9References

30Claims

0Family size

Assignees

PROMETHEUS BIOSCIENCES, INC. · US
Dr. Falk Pharma Gmbh · DE

Inventors

Jessie-Farah FECTEAU · Escondido, US
Mark Renshaw · San Diego, US
Johan Fransson · San Diego, US
Olivier Alexandre Laurent · San Diego, US
Burton Barnett · Rossmoor, US

Key dates

Filing date	Aug 26, 2022
Grant date	Jan 9, 2024
Priority date	—
Expiry date	Aug 26, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.